Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma

Clinical trial NCT02097238 · COMPLETED

Trial details

NCT number: NCT02097238
Sponsor: National Cancer Institute (NCI)
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Osteosarcoma

Start date: 2014-08-01
Primary completion: 2015-06-30
Enrollment: 19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.